Sacituzumab Govitecan Promising in Triple-Negative Breast Cancer

THURSDAY, Feb. 21, 2019 -- An antibody-drug conjugate, sacituzumab govitecan-hziy, shows promise in refractory metastatic triple-negative breast cancer, according to a study published in the Feb. 21 issue of the New England Journal of...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news